Emerging pathways as individualized therapeutic target of multiple myeloma. - Wikidata - awgldk - TriplyDB

Emerging pathways as individualized therapeutic target of multiple myeloma.

Emerging pathways as individualized therapeutic target of multiple myeloma.

http://www.wikidata.org/entity/Q38112176

about

MicroRNAs in multiple myeloma and related bone disease Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.The structural basis for cancer treatment decisions.MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.Multiple Myeloma: Treatment is Getting Individualized In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.MicroRNAs: New therapeutic targets for intestinal barrier dysfunction.MicroRNAs in inflammatory bowel diseases: paradoxes and possibilities.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Mir-221/222 are promising targets for innovative anticancer therapy.Emerging antibodies for the treatment of multiple myeloma.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

P2860

Q26770478-80975948-BD38-4B49-A4E3-92C4014DA8E9 Q27692033-6736A699-61F2-4C90-BFBA-3123B3761250 Q33917555-2834EB0C-99FA-4018-8286-B9416F3EB921 Q34365654-11D1388A-B732-48D4-AD3F-9442C7D2A557 Q35766816-E4463F8E-821C-4AAB-BC34-E67FF165C527 Q36522964-F798B7D6-E740-45E0-A8F7-88389D909805 Q37597751-E248A83F-4DA7-4351-BB60-031924ABC54C Q37619866-A4A6F11A-4FC5-40C6-8BBE-69977FC1FEF1 Q38218209-3F658D13-3481-440F-A2AA-8B81D7B8BB9B Q38219024-E808A22E-D3DE-41EC-BF2F-59FA2C2A3961 Q38407040-3418DD93-86CB-4FD8-8805-B8A004426F2B Q38476564-4188FCB9-7588-409E-9276-65FE12FA0EC0 Q38767024-A1F1646D-C5F7-4D71-A01E-EA71D1271B53 Q38838239-2D284ED5-F1F8-4DAE-A661-CCEE88D017EF Q38854653-80E63603-AECF-46DA-82FE-70BAEA2DDD80 Q40856384-EC86A7CE-D968-490D-96D7-6868B77C7380 Q41894298-467FF3AC-E4BD-442A-8CBF-B3E1AF3B5880 Q47145765-77846942-4301-44B1-A895-64358E71B5CE

P2860

Emerging pathways as individualized therapeutic target of multiple myeloma.

http://www.wikidata.org/entity/Q38112176

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging pathways as individualized therapeutic target of multiple myeloma.

@en

type

label

Emerging pathways as individualized therapeutic target of multiple myeloma.

@en

prefLabel

Emerging pathways as individualized therapeutic target of multiple myeloma.

@en

P1433

Q38112176-2F957FDE-4FC7-4193-AFF8-B9F80BCE2715

P1476

Q38112176-A5565D1C-78F7-423F-9845-D1F273BE12A0

P2093

Q38112176-706061B9-7E2D-4F68-A764-FF971280FB88

Q38112176-78223D3D-2B9C-48E6-AC7E-D48B5307D735

Q38112176-A038C944-8B9F-4193-A24E-7BE58173B876

Q38112176-C58142CC-761F-4DAF-A7A7-083891C79BF5

Q38112176-EAE8B4FB-5E1B-440C-B54D-F0F1D02FCD18

P2860

Q38112176-00763C76-A82E-41B9-9383-360D18B2181B

Q38112176-0BD2B25B-C182-4BA6-86FD-D760A2E22DE7

Q38112176-0C9263CC-1D5D-4A49-A3E0-CE7269631449

Q38112176-0EB94DCC-BBE6-4D16-9E2D-08642FA8EC42

Q38112176-0EECF40A-1E96-452E-B026-B3AEAE98AAAF

Q38112176-10F04A01-8310-4F5F-9806-0DCA3B32082E

Q38112176-11F1187F-BADE-4CCA-BF59-1317EE7135DE

Q38112176-14ABC46B-8F5A-44D9-9B60-606F078FF6FE

Q38112176-14D70AFB-E1BC-4451-944A-6300975FDA05

Q38112176-153B560C-273F-4CAE-A641-06793184F145

P304

Q38112176-D6034DDB-23FC-4B8F-A5E5-546E4FAADE84

P31

Q38112176-AED2B435-9851-41D5-A4F4-3360E5D23220

P356

Q38112176-BAF7261A-BB3D-42EC-9CED-4E7FC539637D

P407

Q38112176-25D0CF4A-031C-4B21-87B5-918B7DA9E696

P478

Q38112176-9D45C984-9408-489C-B525-D45AD2565927

P50

Q38112176-069ACD63-1C5D-4747-A7EE-EEA16F27272B

Q38112176-3ED4E2FE-5624-4993-A6BB-1BF7138EFC8E

Q38112176-6948D543-8E62-47FE-AE52-2BB362FDEB57

P577

Q38112176-6373D5C3-2C19-486C-922C-82DDC229D573

P5875

Q38112176-533B0327-BA25-43DC-B831-D648DB05287F

P698

Q38112176-1E48E90C-4380-4B71-B608-2AF8E1511B05

P356

14712598.2013.807338

P1433

Expert Opinion on Biological Therapy

P1476

Emerging pathways as individualized therapeutic target of multiple myeloma

@en

P2093

Giuseppe De Rosa

http://www.w3.org/2001/XMLSchema#string

Maria Castellano

http://www.w3.org/2001/XMLSchema#string

Pierfrancesco Tassone

http://www.w3.org/2001/XMLSchema#string

Pierosandro Tagliaferri

http://www.w3.org/2001/XMLSchema#string

Silvia Zappavigna

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

Initial genome sequencing and analysis of multiple myeloma

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Clinical significance of TP53 mutation in myeloma.

Clinical and biological significance of RAS mutations in multiple myeloma.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

P304

S95-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2013.807338

http://www.w3.org/2001/XMLSchema#string

P407

P478

13 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Gabriella Misso

Michele Caraglia

Maria Teresa Di Martino

P577

2013-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237058645

http://www.w3.org/2001/XMLSchema#string

P698

23738692

http://www.w3.org/2001/XMLSchema#string